Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12139766 | 0.93 | GAA (0.48) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL25074354 | 0.93 | GAA (0.48) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL12139764 | 0.93 | GAA (0.48) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL10246549 | 0.92 | GAA (0.57) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL18997679 | 0.91 | GAA (0.60) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL25143945 | 0.88 | SIGMAR1 (0.46) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL23594286 | 0.88 | GAA (0.44) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL10244824 | 0.88 | HSD17B10 (0.62) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL12139771 | 0.88 | HSD17B10 (0.73) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL26138890 | 0.86 | PKM (0.43) | GAAALOX15TSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-04-20 | — | — | US | disclosed |
| US-8513231-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fü Kombinatorische Chemie (DE) | 2013-08-20 | — | — | US | disclosed |
| US-8513231-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fü Kombinatorische Chemie (DE) | 2013-08-20 | — | — | US | disclosed |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8329908-B2 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8268812-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fül Kombinatorische Chemie (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2011-03-10 | — | — | US | disclosed |
| US-7820823-B2 | Dual action antibiotics | Morphochem Aktiengesellschaft Fur Kominatorische Chemi (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | GAA 1565/4885ALOX15 4296/4885TSHR 2530/4885 |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | GAA 1214/4885ALOX15 1632/4885TSHR 4392/4885 |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | GAA 1214/4885ALOX15 1632/4885TSHR 4392/4885 |
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | GAA 1565/4885ALOX15 4296/4885TSHR 2530/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | GAA 1214/4885ALOX15 1632/4885TSHR 4392/4885 |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | SLC11A2, MRPL21, MAP2K5 | GAA 260/4885ALOX15 2502/4885TSHR 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.